Fennec pharmaceuticals inc.FENC.US Overview

US StockHealthcare

(No presentation for FENC)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

FENC Overall Performance

FENC AI Analysis & Strategy

FENC Recent Performance

10.49%

Fennec pharmaceuticals inc.

0.81%

Avg of Sector

-1.14%

S&P500

FENC PowerScanner

FENC Key Information

FENC Valuation Metrics

FENC Earnings Table

FENC Profile

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.